How Dutch Pharma Companies Can De-Risk CAPEX Projects Through Structured Consultancy Models

Why CAPEX Projects in Dutch Pharma Are Becoming Harder And What Companies Are Doing About It

A few months ago, we were speaking with someone leading a facility expansion project for a pharmaceutical company in the Netherlands. The conversation started the way these conversations usually do timelines, construction phases, equipment delivery schedules.

Nothing unusual.

But then he said something interesting.

The investment itself isn’t the difficult part. The real challenge starts when the project actually begins.

That comment stuck with us.

Because it reflects something we’ve been hearing more frequently across the Dutch life sciences sector.

Companies are investing heavily in new infrastructure. Laboratories are expanding. Manufacturing capacity is increasing. Entire innovation districts are growing faster than they were ten years ago.

And yet behind many of those projects there is a shared reality: pharmaceutical infrastructure is complicated to deliver.

When Capital Projects Become Real

During the planning stage, most projects look relatively straightforward. Leadership teams define the investment, architects start drawing layouts, and timelines are mapped out.

But once work begins, the situation changes.

Engineers refine technical designs. Operational teams begin thinking about how production will actually function. Equipment suppliers introduce small changes that ripple through the project.

None of this means something is wrong. In fact, these adjustments are completely normal.

The real challenge is coordination.

One decision often affects several other areas of the project. A small design adjustment might change the way production flows through a facility. That change might require new conversations with operational leaders or quality teams.

Suddenly the project environment becomes much more dynamic than it looked during early planning.

Why Pharmaceutical Facilities Are Especially Complex

People outside the industry sometimes assume pharmaceutical facilities are simply advanced manufacturing plants.

In reality they are something closer to ecosystems.

Production environments must remain controlled and consistent. Equipment must operate reliably for years. Operational workflows have to support both efficiency and quality.

These requirements overlap constantly.

A technical change in one area can influence multiple teams at once. Engineers adjust layouts, operational leaders rethink workflows, and project managers suddenly have new decisions to coordinate.

Anyone who has worked inside one of these projects recognizes the pattern immediately.

Things evolve as the project progresses.

The Talent Factor That Appears Later

Another theme we hear frequently from organizations in the Netherlands involves expertise.

Large capital programs need people who understand more than just construction. They require professionals who understand pharmaceutical manufacturing environments as well.

For example:

• engineers who have worked in pharmaceutical facilities before
• project leaders familiar with complex manufacturing infrastructure
• specialists who understand how engineering and operations interact

Many companies already have these people internally.

But when multiple projects are running at the same time which is increasingly common internal teams can become stretched.

That doesn’t mean organizations lack capability. It simply reflects the pace at which the sector is growing.

Why the Netherlands Keeps Attracting Investment

The Dutch life sciences ecosystem has developed a strong reputation internationally.

Part of that comes from the country’s academic environment. Universities and research institutions collaborate closely with industry. Another factor is the concentration of biotechnology companies and pharmaceutical organizations operating within a relatively small geographic area.

Leiden Bio Science Park is probably the most visible example, but it represents a broader national trend.

When research institutions, startups and global pharmaceutical companies operate near each other, innovation tends to accelerate.

And when innovation accelerates, infrastructure projects usually follow.

When Traditional Project Models Start to Strain

For many years companies managed capital projects largely with internal teams supported by contractors.

That approach worked well in stable investment cycles.

But today’s environment looks different.

Projects are larger. Technologies are more specialized. Timelines can be tighter than they were in the past.

At the same time, professionals with experience in pharmaceutical infrastructure are in high demand across Europe.

As a result, many organizations find their internal teams carrying a heavier workload than expected.

Where Structured Consultancy Models Enter the Picture

This is often the moment when organizations start considering structured consultancy support.

Consultancy in this context does not mean outside advisors delivering high-level recommendations and leaving.

More often it means specialists working alongside internal teams during critical phases of a project.

Their contribution might involve helping coordinate technical teams, supporting leadership during complex project stages, or ensuring operational readiness stays aligned with engineering work.

In practical terms, consultancy support can temporarily expand the expertise available within a project.

Internal teams remain responsible for the investment. The consultancy simply strengthens the project environment.

Looking at CAPEX Risk Through Project Phases

Over time we’ve noticed that most capital programs follow a similar rhythm.

First comes strategic alignment. Leadership teams define the purpose and scope of the project.

Then technical design begins. Engineers and operational specialists collaborate to shape the facility.

After that comes execution, often the most intense stage because several teams are working simultaneously.

Finally, there is operational readiness, where the focus shifts toward preparing the facility for real production.

Each stage introduces different challenges.

Projects that manage the transitions between these phases carefully tend to experience fewer surprises later.

What We Continue to Notice Across the Sector

Working with life sciences organizations over the years reveals a few recurring patterns.

Projects tend to move more smoothly when engineering teams and operational leaders collaborate early rather than sequentially.

Clear leadership across multiple teams also makes a significant difference. When someone maintains oversight across disciplines, coordination improves dramatically.

And perhaps most importantly, organizations benefit when expertise can be scaled during demanding phases instead of stretching internal teams across multiple initiatives.

Looking Ahead for the Dutch Life Sciences Industry

Pharmaceutical innovation continues to evolve quickly. New therapies and advanced technologies require increasingly sophisticated infrastructure.

For the Netherlands this presents a real opportunity.

The country already plays an important role in the European life sciences landscape, and continued investment will likely strengthen that position.

But as projects become larger and more technically demanding, the way organizations manage capital programs will matter even more.

Those that combine strong internal leadership with access to additional expertise when needed will likely find these projects far easier to navigate.

FAQ’s

Why are CAPEX projects complex in pharmaceutical manufacturing?
They require controlled environments, specialized equipment and strong cross-team coordination.

What are the main risks in pharmaceutical capital projects?
Engineering changes, project delays and limited expert resources.

How do consultancy models reduce CAPEX risk?
They provide additional expertise and improve project coordination.

Why is the Netherlands a key pharma investment hub?
It has strong research institutions and leading biotech clusters like Leiden.

How can companies better prepare for CAPEX projects?
By aligning teams early and securing the right expertise.

Supporting the Netherlands Life Sciences Sector

Behind every new therapy or research breakthrough sits a complex network of infrastructure.

Facilities, laboratories and production environments make innovation possible.

At SIRE Life Sciences, we work with organizations across the Netherlands to support complex initiatives with practical industry experience and specialized expertise.

If your organization is preparing for a capital investment or facility expansion within the Dutch life sciences sector, we would welcome the opportunity to discuss how structured consultancy approaches could support your project environment.